Select Medical (NYSE:SEM) Holdings Corporation (NYSE:SEM), a leading operator of specialty hospitals, announced on Monday the successful completion of a $650 million offering of senior notes due in 2032 by its subsidiary, Concentra Escrow Issuer Corporation. The notes, bearing an interest rate of 6.875%, were sold in a private offering exempt from registration under the Securities Act of 1933.
The offering is part of Select Medical's strategy to execute a planned separation of Concentra Group Holdings Parent, Inc., which is expected to be completed by merging Concentra Escrow Issuer Corporation with Concentra Health Services, Inc., with the latter assuming all obligations. The proceeds, minus $50 million for general corporate purposes, will be paid to Select Medical Corporation as a dividend.
The senior notes will mature on July 15, 2032, with interest payments commencing January 15, 2025. These notes and their guarantees rank as senior unsecured obligations of the issuer and guarantors, effectively subordinated to any secured debt to the extent of the collateral's value.
The notes are subject to mandatory redemption if the merger is not completed by September 30, 2024, at 100% of their initial issue price plus accrued interest. Moreover, post-merger, the issuer may redeem the notes at a premium before July 15, 2027, or at par thereafter.
The indenture governing the notes contains covenants restricting certain activities, such as incurring additional debt, paying dividends, or making certain investments, to protect the interests of the note holders.
This transaction, based on a press release statement, is not an offer to sell or a solicitation of an offer to buy securities. The notes have not been registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
In other recent news, Select Medical Holdings Corporation's subsidiary, Concentra, has set its initial public offering (IPO) price range between $23.00 to $26.00 per share. The IPO involves 22.5 million shares, with Select Medical maintaining ownership of 104.1 million shares post-IPO. Analysts at Benchmark have raised Select Medical's price target to $48.00, up from $42.00, in light of the IPO announcement.
Concurrently, Concentra has launched a $750 million senior notes offering, part of a broader plan to separate Concentra from Select Medical. The proceeds will be used for corporate expenses and to pay a dividend to Select Medical Corporation.
Select Medical reported a strong first quarter, with a 22% increase in adjusted EBITDA and a 7% rise in revenue year-over-year. RBC Capital and Benchmark have positively assessed the company's performance, leading to raised price targets. These recent developments underline Select Medical's strategic management and resilience amidst industry challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.